New drug combo shows promise in Hard-to-Treat cancers
NCT ID NCT05651022
First seen Jan 17, 2026 · Last updated May 16, 2026 · Updated 16 times
Summary
This early-phase study tests an experimental drug called DECOY20, given alone or with another drug (tislelizumab), in about 120 adults with advanced solid tumors like liver, colorectal, pancreatic, lung, head and neck, bladder, or MSI-high cancers. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. This is not a cure; it aims to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atlantic Health System
Morristown, New Jersey, 07960, United States
-
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, 44195, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Gabrail Cancer & Research Center
Canton, Ohio, 44718, United States
-
Hoag Memorial Hospital Presbyterian
Newport Beach, California, 92663, United States
-
Prisma Health Cancer Institute-ITOR
Greenville, South Carolina, 29605, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263, United States
-
The Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
UH Seidman Cancer Center
Cleveland, Ohio, 44106, United States
-
University of Southern California- Norris Cancer Center
Los Angeles, California, 90033, United States
-
Washington University, Siteman Cancer Center
St Louis, Missouri, 63108, United States
-
Winship Cancer Institute of Emory University
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.